Eurofins Discovery

Drive Your Secondary Pharmacology Forward with Eurofins Discovery! Staying ahead of the latest industry standards, we have expanded our SafetyScreen? offering to help you assess potential safety risks earlier and more comprehensively in your drug discovery program. Aligned with the latest IQ-DruSafe consortium recommendations, we have developed two new SafetyScreen panels to enhance early-stage risk assessment: ·??SafetyScreen18 Core Panel: Focuses on the 18 most critical off-targets early in drug development, including GPCRs, ion channel transporters, and enzymes, enabling the identification of vital safety risks at the earliest stages. ·??SafetyScreen59 Extended Panel: Complements the core panel by adding 33 additional targets, such as kinases, which were not previously evaluated. This expanded coverage allows you to anticipate potential adverse effects sooner, helping to prevent costly late-stage failures. Our gold-standard SafetyScreen44 Panel continues to provide deep insights into off-target interactions. To align with the latest recommendations, you can continue with the SafetyScreen33 Delta Panel, a complementary panel covering all newly recommended targets for a more comprehensive safety assessment. To streamline your analysis, our experts developed In Vitro Safety Insight, an advanced visualization tool designed to help you interpret your results with clarity and precision. Discover more: https://lnkd.in/eeUF4xz4 #Eurofins #DrugDiscovery #Pharmacology #SafetyAssessment #Innovation #IQDruSafe

Meet our team at BIO-Europe in Milan – March 17, 2025! Sahar Davatgarbenam and Paul Ratcliffe will be there to discuss how we can accelerate your drug discovery program, and understand how Eurofins Discovery can support your needs from target validation to IND-enabling. What are the key benefits of choosing Eurofins Discovery: ·?Optimize costs and timelines with our integrated solutions. ·?Connect with industry experts who truly understand your drug discovery challenges. ·?Flexibly access our fully enabling One-Stop-Shop Solutions, with FTE and FFS approaches tailored to your program. Let’s connect to explore how we can support your programs and evolving needs, by commenting on this post or by reaching out directly to our experts! For event details, visit: https://lnkd.in/eRdjEqv To learn more about our capabilities, visit: https://lnkd.in/evmuzHQp #Eurofins #IntegratedDrugDiscovery #BioEuropeSpring?

??Thank You for an Amazing JSPS2025! We are delighted to have participated in JSPS2025, where we had the opportunity to showcase our new SafetyScreen panels that align with the latest recommendations from the IQ DruSafe Leadership Group. Top Questions from the Event: ?What are the SafetyScreen18 & SafetyScreen59 Panels? ?How can Safety Panels help with drug discovery and IND applications? ?Can Eurofins Discovery’s expanded safety panels be customized for my specific compounds? These important questions highlight the growing need for innovative solutions in preclinical safety assessment. Let’s Keep the Conversation Going! If you’re curious about these questions or have more to ask, reach out or learn more about our services here: https://lnkd.in/gffSwWTu Thank you to everyone who visited our booth and spoke with Chun-Yao Lee. Your enthusiasm inspires us to continue driving innovation in safety pharmacology. #JSPS2025 #SafetyPharmacology #DrugDiscovery #Eurofins

We are excited to announce the deployment of Genedata Screener? software as part of our integrated computational platform. Genedata Screener is the gold standard for screening and profiling data analysis. This solution is well suited to support the expansion of Eurofins Discovery Hit Finding services, which include the most advanced HTS technologies, namely Acoustic Ejection Mass Spectrometry and High-throughput Spectral Shift. Read the full release here and learn about how this deployment will accelerate data-driven decision making: https://lnkd.in/g6jsS534 #Eurofins #HitFinding #DataDriven

Ranking Your Biotherapeutics Candidates Surface Plasmon Resonance (SPR) is a label-free technique used to characterize therapeutic antibodies and other biomolecules by measuring real-time interactions with targets. This provides binding kinetics and affinity, offering valuable insights into potential function and mechanism of action, especially when combined with functional cell-based assays. Eurofins Discovery's optimized SPR assays provide consistent results with fast turnaround times. Our expert team delivers essential protein binding data and supports biotherapeutics development with complementary services like protein production and antibody optimization. SPR measures protein-protein interactions, helping to determine binding affinity and specificity. We assess antigen targeting and off-target effects, ensuring optimal lead selection and minimizing safety risks. We provide detailed binding affinity data to understand how therapeutic candidates interact with immune system components, a perfect complement to our ADCC, CDC, and ADCP assessments. Read Our Blog: https://lnkd.in/gR4md-ut #Biotherapeutics #DrugDiscovery #Eurofins

Confidently Measure Your Candidate's Effector Function ADCC, CDC, and ADCP assays are essential for evaluating your therapeutic antibody’s ability to target immune cells, providing insights into its efficacy, mechanism of action, and safety. These assays are pivotal in guiding antibody optimization for monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and other antibody-based therapies. At Eurofins Discovery, our Immunology experts are leaders in assessing effector functions for therapeutic candidates. We support ADC development and determine if your mAbs induce cytotoxicity. We also offer assays such as FcγR, FcRn, and C1q binding to complement your functional characterization. Our team can develop ADCC, CDC, and ADCP assays using colorimetric, chemiluminescent, or fluorescent methods, providing tailored solutions to accelerate your antibody development program. Let us help move your research forward with our trusted cytotoxicity assays. Read the Case Study: https://lnkd.in/gzja7-Du #Biotherapeutics #DrugDiscovery #Eurofins

Looking for personalized support in your drug discovery programs? Meet Sahar Davatgarbenam and Carol Austin at BioLabs Investor Days 2025 in Paris on March 11 to explore how Eurofins Discovery can support your quest for new therapeutic solutions. De-risk your portfolio with us, taking advantage of our Chemistry & Biology global centers of excellence. With over 12,000 off-the-shelf assays, we offer custom solutions using cutting-edge technologies with a flexible approach, from individual proof-of-concept packages to fully integrated programs, fee-for-service, and full-time equivalent options. What makes Eurofins Discovery your best partner? ? High-quality data with expedited turnaround times ? Modality agnostic, covering small molecules, biologics & gene therapies ? Fully integrated programs with dedicated teams ? Comprehensive capabilities and scientific expertise across all stages of drug discovery ? Adapted and flexible service agreements for seamless project coordination Let’s connect to explore how we can support your programs and evolving needs. For event details, visit: https://www.biolabs.io/ #Eurofins #IntegratedDrugDiscovery #BioLabs2025 #InvestorDays?

Drive oncology research with Eurofins Discovery’s helicase enzymatic panel! Helicases are crucial enzymes that drive key cellular processes, including DNA replication, transcription, recombination, ribosome biogenesis, and repair. Their significant role in the proliferation of cancer cells and viruses makes them critical targets for drug discovery. At Eurofins Discovery, we are meeting the challenge head-on by accelerating drug discovery through our integrated helicase solutions. Our comprehensive helicase services currently include: ·???????15 helicase proteins ·???????15 ATPase activity assays, available as standalone or panel formats ·???????3 unwinding activity assays ·???????Proof of concept on PolQ target engagement ·???????6 helicases compatible with SPR for biophysical analysis Explore our complete range of helicase enzymatic solutions, from panels to standalone and customized tests here: https://lnkd.in/gpEgeHED #Helicase #ScientificInnovation #Oncology #Eurofins

SH2scan is the only commercially available platform to efficiently investigate therapies targeting SH2 domains that disrupt protein-protein interactions, inhibit allosteric sites, or allow for the development of a protein degrader. This new service offers 102 assays for human wild-type and mutant targets against target families including STATs, kinases, phosphatases, phospholipases, E3 ligases, adaptor proteins, GEFs, and signal regulators. ? SH2scan provides you: ? Flexible assay usage for primary single-concentration screening, secondary dose-response profiling, or selectivity screening across all SH2scan assays. ? Inter-domain potency rank-ordering and SAR with a broad dynamic range (micromolar to picomolar). ? High-throughput screening capabilities for hit-to-lead campaigns. ? Custom assay development capabilities. Find out more: https://lnkd.in/g4mxtau6 #drugdiscovery #eurofins

?? Join Us at #JSPS2025 in Osaka! ?? We are excited to participate in JSPS 2025, the annual meeting of the Japan Safety Pharmacology Society, taking place February 20-21, 2025, in Osaka, Japan. Visit us at Booth #24 to explore how we support drug discovery and preclinical safety assessment with our comprehensive SafetyScreen?and SAFETYscan panels! Spotlight NEW Services at JSPS2025: ?SafetyScreen 18 – A rapid and cost-effective screening panel covering key off-target liabilities. ?SafetyScreen 59 – A more extensive panel providing deeper insights into potential safety risks. ?Expanded SafetyScreen Panels – Tailored solutions to meet your specific safety pharmacology needs. Meet Our Team! Our Managing Director, Chun-Yao Lee, with 24 years of experience in pharmacology, will be on-site to discuss how our integrated preclinical solutions can accelerate your drug discovery pipeline. Let’s connect! Stop by Booth #24 or schedule a meeting in advance. ?? Learn more about our Safety Panels: https://lnkd.in/gffSwWTu #SafetyPharmacology #DrugDiscovery